Par Pharmaceutical Companies, Inc.™ (NYSE:PRX) develops, manufactures and markets generic drugs and innovative proprietary pharmaceuticals for specialty markets.

Par’s Generics Division is committed to providing high-quality pharmaceuticals that are affordable and accessible to patients. According to IMS Health, Par ranks in the top 10 in U.S. sales among all generic drug companies. The company currently manufactures, markets or licenses generic prescription drugs in 85 product families.

Par's Branded Products Division was launched in 2005 with the approval of Megace^® ES. In September 2007, Par's Branded pharmaceuticals business was renamed Strativa Pharmaceuticals. With an experienced management team and strong commercial infrastructure in the supportive care segment, Strativa has in-licensed four proprietary drugs in development: Zensana™ (ondansetron HCL) Oral Spray, Loramyc™ (miconazole Lauriad^®), ONCONASE^® (ranpirnase), and thin film ondansetron. Each of these development-stage drugs was in-licensed with the goal of leveraging Strativa's management and commercial infrastructure.

Headquartered in Woodcliff Lake, N.J., and with manufacturing in Spring Valley, N.Y., and R&D facilities there and in Somerset, N.J., Par employs 720 people. Detailed information about Par for investors and for the media is provided elsewhere on this web site.

MORE ...